You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Gubra: Understanding valuation (PoS) post Abbvie deal
The company combines the best of both worlds – a fast-growing, cash-generating CRO business serving top pharma companies and a high-risk, high-reward drug discovery pipeline. A landmark partnership with AbbVie, which includes upfront payments of USD 350m for its obesity drug, GUBamy, highlights its innovation potential.
With advanced AI platforms and new candidates like UCN2 in the pipeline, Gubra is positioned at the frontier of biotech. Watch the video to understand what the market is pricing in – and what could unlock further development?
Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility subscription agreement. The commentary is for informational purposes only and does not contain recommendations to buy, not to buy, sell or not to sell shares. / Philip Coombes 08:55 26/03/2025